Cardiff Oncology Sues NMS Over Critical Onvansertib License Dispute
CRDF sits 20% above its 52-week low of $1.48 on elevated volume (4.1× avg).
Summary
Cardiff Oncology has filed a lawsuit against Nerviano Medical Sciences to protect its license agreement for onvansertib, its lead drug, escalating a critical dispute over patent inventorship.
Key Events · Legal and Risk Events · CRDF
-
Lawsuit Filed Over Onvansertib License
Cardiff Oncology initiated a lawsuit against Nerviano Medical Sciences (NMS) in federal court to dispute NMS's claim of material breach of the license agreement for onvansertib.
-
Seeks Injunctive Relief and Declaratory Judgment
The company is seeking injunctive relief to compel NMS to continue performing under the agreement and a declaratory judgment that Cardiff did not breach the terms.
-
Dispute Over Patent Inventorship
The core of the dispute involves NMS's allegation that Cardiff failed to name an NMS employee as a joint inventor on two U.S. patents related to onvansertib.
-
Critical for Company's Future
Onvansertib is Cardiff's lead drug, and the resolution of this license dispute is critical for the company, which recently reported a "going concern" warning and a short cash runway.
Analysis · CRDF · Life Sciences
Cardiff Oncology has escalated its critical license dispute with Nerviano Medical Sciences (NMS) by filing a lawsuit. This action seeks to prevent NMS from terminating the license agreement for onvansertib, the company's lead drug, and obtain a declaratory judgment that Cardiff did not breach the agreement. The dispute centers on inventorship claims for key patents. Given Cardiff's "going concern" warning and short cash runway, the outcome of this litigation is paramount to the company's future, as onvansertib is its primary asset, especially after recent positive FDA agreement on Phase 3 trial design.
At the time of this filing, CRDF was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.3M. The 52-week trading range was $1.48 to $4.56. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.